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2EXPLANATORY MEMORANDUM
The global crisis:
Communicable diseases not only cause considerable poverty but are also the consequence of
poverty in developing countries, particularly in Sub-Saharan Africa. HIV/AIDS, malaria and
tuberculosis (TB) alone cause more than 5 million deaths every year, with 95% of these in the
developing world. Since poverty itself contributes to the spread of these diseases, this vicious
circle of disease and poverty causes a fundamental public health and economic crisis.
This crisis requires a dramatic solution that is beyond the resources of individual governments
and is at the centre of the international political debate with calls for urgent action (EC Round
table 2000, G8 Communication of Okinawa 2000, UNGASS 2001). In response to this
emergency, the Commission has launched its Programme for Action : Accelerated action on
HIV/AIDS, malaria and TB in the context of poverty reduction. The Council and the
Parliament emphasised the gravity of the HIV/AIDS, malaria and TB epidemics and the need
to increase support at national, regional and global levels in their response to the policy
framework and the Programme for Action presented by the Commission in 2000 and 2001
(Resolutions of 10 November 2000, 14 May and 4 October 2001).
This Programme for Action creates a broad policy framework for a comprehensive, global,
multi-sectoral approach to poverty-related diseases based on improving the impact of existing
interventions, increasing affordability of key pharmaceuticals, and developing new and more
effective health products. In this context the Commission has proposed to establish a clinical
trials programme responding to the needs of Developing countries. The goal is to accelerate
the development of new clinical interventions to fight HIV/AIDS, malaria and TB in the
Developing countries.
Current situation:
Member States and Associated States will invest more than € 1 billion for the years 2002-
2007 in basic and clinical research to develop new clinical interventions against HIV/AIDS,
malaria and TB. However, although vast quantities of relevant research results are being
generated, they are failing to be translated into health improvement tools that are applicable in
the Developing countries. The decreased efficiency and impact of the individual states’
investments is caused by :
1) lack of adequate networking and co-ordination between the European national
programmes resulting in fragmentation of European research in this field;
2) major organisational and economic impediments to conduct clinical trials of
sufficient size and ambition to achieve meaningful results;
3) insufficient involvement of the Developing countries where the target diseases are
endemic, often due to lack of adequate clinical research facilities and trained human
resources.
The European and Developing countries Clinical Trials Partnership
14 EU Member States and Norway have recognised that a political commitment is required to
overcome these problems. In order to exploit Europe’s investment to confront HIV/AIDS,
malaria and TB in the Developing countries, and mobilised and supported by the European
3Commission, they are creating the “European and Developing countries Clinical Trials
Partnership (EDCTP)” as a flagship initiative to accelerate the development of new clinical
interventions to fight these diseases, particularly in Sub-Saharan Africa.
The EDCTP is unprecedented in scope and ambition and unites practically all the relevant
clinical research and development activities undertaken by 14 EU Member States and Norway
together with that of the Community. The EDCTP will also provide an urgently needed “pull”
to encourage and accelerate more basic research and pre-clinical research in this field.
The overall goal of the EDCTP is to accelerate the development and evaluation of new
vaccines, drugs and other preventive or therapeutic tools against HIV/AIDS, malaria and TB
in full partnership between Europe and the Developing countries. Research activities carried
out within the framework of the EDCTP will respect fundamental ethical principles, including
those which are reflected in Article 6 of the Treaty of the European Union and in the Charter
of Fundamental Rights of the European Union.
This new partnership builds on a joint programme of clinical research activities in Europe and
in the Developing countries. The EDCTP has the following three major objectives, which are
coherent with EU-research, trade and development policies:
1) Networking and co-operation between the participating national programmes to
increase their efficiency and impact and overcome the fragmentation of European
research in this field. The most powerful means of networking research programmes
is by the joint implementation of programmes or large parts of programmes. This
will contribute to realising the principles of the European Research Area in this field
of research.
2) Acceleration of the development of new products by supporting clinical trials in the
Developing countries, thus promoting transfer of research into clinical practice
thereby strengthening Europe’s R & D excellence on the global market.
3) Strengthening clinical research capacities in the Developing countries in the fight
against the three poverty-related diseases, in line with European development and co-
operation objectives. This aim would also help establish a long term sustainable and
genuine partnership between Europe and the Developing countries.
The EDCTP joint programme will link and provide a range of services designed to support
the networking and co-operation of national programmes, support for clinical trials from the
public and private sectors, particularly the establishment of new public-private partnerships to
help advance new affordable and effective medical products through clinical trials, and to
strengthen the logistic, clinical and laboratory research capacities in Developing countries to
conduct clinical trials including training schemes and support to local ethical review systems.
A robust and dynamic legal entity is needed for the EDCTP to be able to respond to the
challenges in a flexible manner. A European Economic Interest Grouping is seen as a suitable
legal structure for the EDCTP joint programme, as it specifically allows the creation of new
activities based on those of its members.
The participating countries recognise that the EDCTP cannot achieve its goal without genuine
participation of the Developing countries. The development of new health products should
meet the needs of the Developing countries and be determined by them. Without active
programmes to strengthen and develop capacity in the Developing countries, those countries
4will not be able to play the critical role expected of them in the partnership. Therefore,
Developing countries share ownership of this initiative by fully participating in the
development and implementation of the EDCTP strategic priorities through representation in
the EDCTP executive structures. In addition the EDCTP encourages the participation of
WHO and other public or private organisations in the EDCTP’s programme.
Community funding of the EDCTP
The report on Macroeconomics and Health commissioned by WHO states a need for 3
billions of Dollars per year for additional investments in biomedical and health research to
successfully confront the three diseases through the development of new efficient
interventions as global public goods. The development of each new vaccine, drug or other
innovative treatments requires large-scale clinical trials in Developing countries costing
several hundred million Euros. The financial goal of € 600 million in the first five years of the
EDCTP reflects the dimension of the problem, the need for mobilisation of different
stakeholders and the challenges that have to be overcome to significantly advance new
clinical interventions.
The Community contribution of € 200 million is calculated to be the substantial but minimum
investment necessary to initiate the EDCTP programme in its first five years. The Community
contribution should be seen as a catalyst to ensure that a number of promising new health
products are quickly brought into clinical trials, to create the legal structure to establish the
EDCTP, and to support a capacity building and training programme in the Developing
countries. It provides incentives for the co-operation of national activities, and creates added
value and critical mass at the European and Developing countries levels. Thus the Community
contribution is essential to create this coherent approach bringing together the stakeholders
committed to the EDCTP objectives, and to help ensure its sustainable long-term
development.
Article 169 as the appropriate instrument for funding the EDCTP
The fundamental basis of the EDCTP initiative is the joint programme formed by the
participating Member States’ and Associated State’s national programmes and the
Community.
Article 169 of the Treaty specifically allows the Community to make provision, in
implementing the Framework Programme, for participation in research and development
programmes undertaken by several Member States. Therefore the framework of Article 169 is
particularly well adapted to implement the EDCTP initiative as it allows the participation of
the Community in the joint programme.
It ensures the effectiveness of Europe’s investment in national clinical research programmes
by providing a common platform that can exploit research results to develop new clinical
interventions against HIV/AIDS, malaria and TB for the benefit of the Developing countries.
The expected impact at the European level will be greater than the sum of the impacts of
national programmes. It will achieve the required critical mass, both in human and financial
terms, by bringing together the available complementary expertise and resources to accelerate
the development of the new medical products urgently needed to reduce the devastating
impact of these three diseases.
Furthermore, at the global level it contributes to a unified voice to represent European
research contributions in the fight against the three diseases in the Developing countries.
5Finally, it promotes a long-term structuring effect both in European and developing countries’
research policy and helps to integrate different policies in a coherent context.
The European Community’s Sixth Framework Programme for Research makes provision to
establish a clinical trials programme. Article 169 of the Treaty is the appropriate instrument
for the Community to support the EDCTP initiative since it allows for both the coordination
of national research programmes and the participation of the Community in the joint
programme.
Time-scale of this initiative
Since June 2001, representatives from 14 Member States - Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Portugal, Spain, Sweden and
the United Kingdom - and Norway - have been working together with the Commission to
develop the concept of the EDCTP in close partnership with Developing countries. They have
developed and agreed a strategic “Concept Document” as a starting point for further
elaborating the initiative. This document, which accompanies this proposal without being part
of it, describes the concept of the partnership and the foreseen EDCTP joint programme goals,
activities and implementation modalities.
Based on this Concept Document the participating States are developing the legal, financial
and operational procedures to allow EDCTP activities to begin in Spring 2003, and initiation
of the first EDCTP-funded clinical trials and capacity building and training programmes by
the end of 2003.
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Proposal for a
DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
on Community participation in a research and development programme aimed at
developing new clinical interventions to combat HIV/AIDS, malaria and tuberculosis
through a long term partnership between Europe and the developing countries,
undertaken by a number of Member States and Norway
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty establishing the European Community, and in particular
Articles 169 and 172, second subparagraph, thereof,
Having regard to the proposal from the Commission1,
Having regard to the opinion of the Economic and Social Committee2,
Acting in accordance with the procedure laid down in Article 251 of the Treaty3,
Whereas:
(1) Decision … /… /EC of the European Parliament and of the Council of ... concerning the
Sixth Framework Programme of the European Community for research, technological
development and demonstration activities aimed at contributing toward the creation of
the European Research Area and innovation (2002-2006)4 (hereafter referred to as "the
sixth framework programme") provides for Community participation in research and
development programmes undertaken at the initiative of a number of Member States,
including participation in the structures created for the execution of those programmes,
within the meaning of Article 169 of the Treaty.
(2) On 30 May 2001, the Commission presented a communication on the application of
Article 169 and the networking of national programmes 5.
(3) In its Resolutions of 10 November 2000 and 14 May 2001, the Council underlined the
gravity of the HIV/AIDS, malaria and tuberculosis epidemics and the need to step up
efforts to increase aid at national, regional and world level.
(4) The European Parliament has adopted a resolution and produced a report6 concerning
the Commission communications on accelerated action on the main communicable
diseases in the context of poverty reduction.
                                               
1 OJ C , , p. .
2 OJ C [… ], [ … ], p. [… ].
3 OJ C , , p. .
4 OJ L [… ], [… ], p. [… ].
5 COM(2001)282 final
7(5) In its conclusions of 30 October 2001, the Council called on Member States to select
specific areas for pilot programmes, for which Community participation in research
and development programmes undertaken at the initiative of a number of Member
States within the meaning of Article 169 of the Treaty would be appropriate, if
necessary in close collaboration with the Commission.
(6) In connection with its communications to the Council and the European Parliament of
20 September 20007 and 21 February 20018, the Commission has presented an action
programme aimed at combating the global problem of HIV/AIDS, malaria and
tuberculosis and identifying various strategies to be implemented. This action
programme has a research and development part aimed among other things at
developing, in coordination with the application of this decision, new clinical
interventions to combat the three diseases through a long term partnership between
Europe and the developing countries.
(7) In their Decision No 36/2002/EC of 19 December 20019 the European Parliament and
the Council decided that the Community would contribute €60 million for the year
2001 to the global fund to fight HIV/AIDS, tuberculosis and malaria.
(8) Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the
Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom (hereafter
known as "the participating States") are undertaking individual national research and
development programmes or activities aimed at developing new clinical interventions
to combat the global problem of HIV/AIDS, malaria and tuberculosis. These
programmes or activities, the required funds for which have been granted, form part of
a long-term partnership.
(9) At present, the research and development programmes or activities undertaken
individually at national level are not the subject of coordination at European level and
do not allow a coherent approach at European level for an effective campaign against
HIV/AIDS, malaria and tuberculosis.
(10) Wishing to have a coherent approach at European level and to act effectively against
HIV/AIDS, malaria and tuberculosis, the participating States agreed to establish a
partnership on clinical trials between European countries and the developing countries
in order to obtain a critical mass in terms of human and financial resources and the
combination of additional expertise and resources available in various countries across
Europe.
(11) To give effect to this partnership, the participating States have developed, with
developing countries, a research and development programme entitled "The European
and Developing countries Clinical Trials Partnership (hereafter referred to as the
EDCTP Programme).
(12) The objective of the EDCTP Programme, the cost of which is estimated by
participating States at €600 million over a five year period, is to accelerate the
development of new clinical interventions to fight HIV/AIDS, malaria and
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8 COM(2001)96 final
9 OJ L 7, 11.01.2002, p. 1.
8tuberculosis in the developing countries, particularly in Sub Saharan Africa. The
EDCTP Programme has been drawn up with a view to stepping up cooperation and the
networking of European national programmes, accelerating clinical trails of new
products in the developing countries, helping to strengthen capacities in the
developing countries and obtaining additional funds to fight these diseases.
(13) The participating States have agreed to develop jointly activities aimed at contributing
to the EDCTP Programme for a period of five years. The overall value of their
contribution is estimated at €200 million.
(14) Activities linked to obtaining additional funds, whether public or private, estimated at
€200 million are provided for in the implementation of the EDCTP Programme.
(15) In order to increase the impact of the EDCTP Programme, the Community should
participate in this programme with a financial contribution of €200 million.
(16) The participating States have decided to create a common structure to implement the
EDCTP Programme which will be the sole beneficiary of the Community contribution.
This structure is a legal entity which will guarantee the Community dimension in
carrying out the EDCTP Programme.
(17) Given that the EDCTP Programme meets the scientific objectives of the sixth
framework programme and that the research field of the EDCTP Programme falls
within the priority theme "Life sciences, genomics and biotechnology for health" of
the sixth framework programme, the financial contribution from the Community
should be taken from the budget allocated to that priority theme.
(18) As the EDCTP Programme is being undertaken jointly by several participating States,
it should be stipulated that those states are jointly and severally liable for carrying out
the activities undertaken under the programme.
(19) It is essential that the research activities carried out under the EDCTP Programme
conform to basic ethical principles, particularly those set out in Article 6 of the Treaty
on the European Union and in the Charter of Fundamental Rights of the European
Union.
HAVE ADOPTED THIS DECISION:
Article 1
1. In implementing the sixth framework programme of the European Community for
research, technological development and demonstration activities aimed at contributing
towards the creation of the European Research Area (2002-2006) (hereafter referred to
as "the sixth framework programme"), adopted by Decision ../../EC, the Community
shall make a financial contribution to the research and development programme
entitled "The European and Developing countries Clinical Trials Partnership"
(hereafter referred to as "the EDCTP Programme") undertaken jointly by Austria,
Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the
Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom (hereafter
referred to as "the participating States").
92. The Community shall pay a financial contribution amounting to a maximum of
€200 million for the duration of the sixth framework programme.
3. The financial contribution from the Community shall be paid from the appropriation
allocated to the priority theme "Life sciences, genomics and biotechnology for
health" of the specific programme of the sixth framework programme "Integrating
and strengthening Community research".
Article 2
1. The financial contribution from the Community shall be conditional upon the
execution of the activities under the EDCTP Programme referred to in the annex to
this decision and the implementation of the research and development programmes
undertaken at national level by the participating States.
2. The financial contribution form the Community shall be paid to the structure created
by the participating States for the implementation of the EDCTP Programme
(hereafter referred to as "common structure") which shall be endowed with legal
personality.
3. The arrangements for the financial participation of the Community and the rules
relating to intellectual property rights shall be adopted jointly by means of an
agreement to be concluded between the Commission and the common structure, in
accordance with the financial regulation application to the Community budget.
Article 3
The participating States shall be jointly and severally liable for carrying out the activities
described in the annex.
Article 4
The Commission and the Court of Auditors may, through their officials or agents, carry out
all the checks and inspections needed to ensure proper management of the Community funds
and protect the financial interests of the Community against any fraud or irregularity. To this
end, the participating States and the common structure shall make all relevant documents
available to the Commission and the Court of Auditors.
Article 5
The Commission shall communicate all relevant information to the European Parliament, the
Council and the Court of Auditors, and calls on the participating States and the common
structure to forward any additional information required by the European Parliament, the
Council and the Court of Auditors concerning the financial management of the common
structure.
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Article 6
This decision is addressed to the Member States.
Done at Brussels,
For the European Parliament For the Council
The President The President
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ANNEX
Description of the activities of the EDCTP Programme
In cooperation with developing countries, the participating States have drawn up a research
and development programme entitled the European and Developing countries Clinical Trials
Partnership (EDCTP).
There are several types of activities under the EDCTP Programme to which the Community
makes a financial contribution in accordance with the procedures to be laid down in the
agreement between the Commission and the common structure:
1. Activities linked to networking and coordination:
· of European national programmes;
· of the activities carried out in the developing countries.
These activities are aimed at strengthening the two main components of the EDCTP
Programme: programmes/activities in Europe on the one hand and in the developing countries
on the other.
2. Activities linked directly to the development of new products against the three
diseases (HIV/AIDS, malaria and tuberculosis):
· support for clinical trials in the developing countries;
· strengthening of capacities in the developing countries.
3. Activities planned to ensure the development, visibility and sustainability of the
EDCTP Programme:
· activities to promote the EDCTP Programme to ensure a high profile at European or
international level;
· activities linked to obtaining the necessary funds to enable the EDCTP Programme to
develop as planned, including beyond the period covered by this decision.
4. Basic activities for the EDCTP Programme such as secretariat services and the
management of information concerning clinical interventions against the three diseases.
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LEGISLATIVE FINANCIAL STATEMENT
Policy area: Research
Activities: research activities pursuant to the EC Treaty.
TITLE OF ACTION:
Proposal for a
DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
on Community participation in a research and development programme aimed at
developing new clinical interventions to combat HIV/AIDS, malaria and tuberculosis
through a long term partnership between Europe and the developing countries,
undertaken by a number of Member States and Norway.
1. BUDGET LINE(S) + HEADING(S)
Subsection B6 6 Indirect actions, B6 611 "Life sciences, genomics and biotechnology
for health".
2. OVERALL FIGURES
2.1. Total allocation for action: €200 million for commitment
2.2. Period of application
2003-2006
2.3. Overall multiannual estimate of expenditure:
a) Schedule of commitment appropriations/payment appropriations (financial intervention)
(see. point 5)
€ million
2003 2004 2005 2006 2007 + Total
Commitments 200 - 200
Payments 20 30 50 60 40 200
This estimate assumes that the EDCTP is fully operational in early 2003.
2.4. Compatibility with financial programming and financial perspective
þ Proposal is compatible with existing financial programming.
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¨ Proposal will entail reprogramming of the relevant heading in the financial
perspective.
¨ Proposal may require application of the provisions of the interinstitutional
agreement.
3. LEGAL BASIS
Article 169 of the EC Treaty.
Decision of the European Parliament and of the Council concerning the multiannual
framework programme 2002-2006 of the European Community for research,
technological development and demonstration activities aimed at contributing towards
the creation of the European Research Area.
Amended proposal for a Council Decision concerning the specific programme
“Integrating and strengthening the European Research Area” implementing the Sixth
framework programme of the European Community for research, technological
development and demonstration activities.
4. DESCRIPTION AND GROUNDS
4.1. General Background
In Europe, more than 80% of public research work on behalf of the developing countries is
carried out at national level, particularly under national or regional research programmes.
There is, however, little in the way of coordination between the national research programmes
themselves or with Community programmes.
As endorsed by the Lisbon European Council in March 2000 and fully supported by subsequent
European Councils, the objective of the European Research Area project is to remove the
barriers between research activities in Europe. To this end, it entails greater coherence and
coordination of national research activities.
The most powerful form of networking is the joint execution of complete programmes or major
parts of programmes.
An explicit part of the objective of helping to achieve the European Research Area, the
Community research framework programme 2002-2006, as proposed by the Commission,
provides for Community participation in national research programmes carried out jointly, under
Article 169 of the Treaty.
Use of Article 169, which has not so far been used:
– is a particularly appropriate means of implementing, in conjunction with other
instruments, a framework programme specifically designed to help achieve the
European Research Area;
– is an effective means of stimulating cooperation and coordination of research activities
carried out at national or regional level in Europe;
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– will also make it possible to achieve results which could not be obtained with the two
other new instruments (networks of excellence and integrated projects), because of the
scale and diversity of the resources employed and the structural effects of the
combination of efforts organised at national level.
Such participation requires well defined actions or initiatives (whether or not they are formally
called "programmes"), on a specific theme or in a specific area, allocated a separate budget and
implemented over a certain period with the aid of clearly defined procedures.
4.2. Need for Community intervention
Three major communicable diseases (HIV/AIDS, malaria, tuberculosis) affect the developing
countries to an extent that their economic and social development is undermined. Alleviation of
poverty in developing countries by combating these three major diseases has emerged as a
primary objective of the European Community’s policies, and it is one of the seven priorities of
the Commission’s Action Plan for 2002. In the Commission's policy framework "Programme for
Action on Poverty-Related Diseases", one part of the action relates to enhancing public financing
and European coordination for the development of new health products to confront the three
diseases, especially in the developing world. In this context, DG Research proposes to participate
in the creation of the European and Developing countries Clinical Trials Partnership with the
ultimate aim of supporting clinical trials for new products to fight HIV/AIDS, malaria and
tuberculosis in the developing countries.
At national level, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy,
Norway, Portugal, Spain, Sweden, the Netherlands and the United Kingdom (participating
States) invest significant resources, amounting to more than €200 million annually, in research
programmes and related activities directed at developing new interventions against the three
poverty-related diseases. However, while it is recognised that large amounts of important
research results are generated, these often fall short of actually being transformed into clinical
interventions applicable in the developing countries.
This shortcoming which decreases efficiency and impact of the individual participating States'
investments in clinical research for HIV/AIDS, malaria and tuberculosis is caused by:
(1) lack of adequate networking and co-ordination between the European national
programmes causing fragmentation of European research in this field;
(2) major organisational and economic impediments to conducting clinical trials of
sufficient size and ambition to achieve meaningful results;
(3) insufficient involvement of the developing countries where the target diseases are
endemic, often due to lack of sufficiently developed local clinical research facilities or
sufficiently trained human resources.
4.3. Objectives of the intervention
To address the above mentioned shortcoming, the participating States have formed the
“European and Developing countries Clinical Trials Partnership (EDCTP)” which accordingly is
based on the following three major objectives intrinsically linked to overall European policies:
– Improvement of networking and co-operation between the participating national
programmes aimed at increasing their efficiency and impact, thus overcoming the
fragmentation of European research in this field and contributing to structuring the
European Research Area.
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– Acceleration of the development of new interventions by supporting and/or funding
clinical trials, thus promoting technology transfer from research results into clinical
application, thereby strengthening Europe’s competitiveness on the global market.
– Strengthening the clinical research capacities in the developing countries for
establishing a sustainable long term and genuine partnership between Europe and the
developing countries in the fight against the three poverty-related diseases. This will
contribute to European development and co-operation policies.
The participating States have agreed to pool the activities of their relevant national programmes
that directly contribute to the EDCTP’s objectives by subscribing to the EDCTP’s Programme of
activities.
4.4. Actions envisaged and means of financing
In cooperation with the developing countries, the participating States have drawn up a research
and development programme: "the European and Developing countries Clinical Trials
Partnership (EDCTP) with a budget of €600 million over the initial period of five years.
€200 million will come from the participating States and €200 million from the Community, the
sum of these budgets being sufficient and necessary to launch and develop the EDCTP
Programme. Moreover €200 million will have to come from other donors, including industry.
The breakdown of the budget according to type of activity is as follows:
– Basic activities for the EDCTP Programme such as secretariat services (budget of
€15 million, foreseen to cover personnel costs of staff members of a modest-sized
central office, for office rent and the acquisition of essential office facilities and
services, and for the obligatory statutory meetings of the organisation’s legal bodies)
and management of information on clinical research into new products to combat the
three diseases in particular for developing countries (budget of €5 million for
informatics infrastructures, set-up and continuous conduct of information surveys).
Activities linked to networking and coordination:
– European national programmes (budget of €15 million to support co-ordination
activities such as joint programme meetings and measures for information exchange,
and to provide incentives for the joint implementation of clinical research activities
including clinical trials as well as to open national programmes for participating groups
from other countries);
– activities carried out in the developing countries (budget of €5 million, to establish and
maintain an appropriately staffed EDCTP branch office in Africa, for office rent and
infrastructure including the essential set-up of satellite telecommunication systems, and
to foster South-South networking, in particular the formation of an operational DC
Coordinating Committee).
These activities are aimed at strengthening the two main components of the EDCTP Programme:
programmes/activities in Europe on the one hand and in the developing countries on the other.
Activities linked directly to the development of new products to combat the three diseases
(HIV/AIDS, malaria and tuberculosis):
– Support for clinical trials. Whereas in the EDCTP programme, the budget allocated for
clinical trials is €400 million, it is estimated that €250 million is sufficient and
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necessary to launch and develop this activity (initially, €250 million can support 10-20
extended efficacy trials to be conducted in Africa, including trials sites maintenance for
3 years); the remaining €150 million have to be generated by other sources, including
industry.
– Strengthening of capacities in the developing countries. Whereas in the EDCTP
programme, the budget allocated for this purpose is €150 million, it is estimated that
€100 million is sufficient and necessary to launch and develop this activity, covering
costs for research support to build up/strengthen an initial number of about 10-20
centralised clinical testing facilities, and to finance a number of training schemes for
African clinicians, scientists, and technical personnel both in Europe and in Africa. The
remaining €50 million will have to be generated from other sources.
Activities planned to ensure the development, visibility and sustainability of the EDCTP
programme (€10 million):
– Activities to promote the EDCTP programme to ensure a high profile and to develop the
following activities: costs for professional internet presence, production of information
material, conduct of press conferences and representation of the EDCTP at meetings of
other global initiatives and relevant international scientific meetings);
– Activities linked to seeking the necessary funds (which may come from industry or
other donors) to enable the EDCTP programme to develop as planned (costs of a
number of professionally conducted fund-raising campaigns which require contracting
consultant and media services);
The participating States will create a European Economic Interest Grouping, the «EDCTP–
EEIG» as a dynamic and flexible legal entity to execute the EDCTP’s Programme.
Community funding as well as contributions from other donors and industry will be directed to
this EDCTP–EEIG as the legal structure responsible for the execution of the EDCTP
Programme’s activities.
5. FINANCIAL IMPACT
5.1 Total financial impact on Part B (over the entire programming period)
5.1.1 Financial intervention - Commitments in € million
Breakdown by objective Total
Integrating and strengthening Community research 12 585
Life sciences, genomics and biotechnology for health 2 255
Life sciences, genomics and biotechnology for health 2003 477.9
Budget allocated under the EDCTP programme 200
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6. IMPACT ON STAFF AND ADMINISTRATIVE EXPENDITURE
Administrative follow-up of the EDCTP programme during the initial five-year phase
comes under total administrative costs for research.
7. FOLLOW-UP E AND EVALUATION
7.1 Follow-up arrangements
The EDCTP programme will be followed up in accordance with the arrangements set
out in the agreement between the Commission and the EDCTP-EEIG.
7.2 Arrangements and schedule for evaluation
– Evaluation of the EDCTP programme: The Commission, where appropriate with the
aid of suitable experts, constantly monitors the progress of the EDCTP programme in
relation to the objectives set. In particular it assesses whether the objectives, priorities,
activities, financial means and management are always in line with the reality of the
situation.
– Annual report: The situation with regard to implementation of Article 169 of the
Treaty is published in the annual report on the Framework Programme presented to the
European Parliament and Council pursuant to Article 173 of the Treaty. This will
include among other things the results of the evaluation of the EDCTP programme, a
description of the activities carried out in connection with research and technological
development, creation of the European Research Area and dissemination of results
during the previous year and the work programme for the current year.
8. ANTI-FRAUD MEASURES
In submitting the reports which could lead to the consolidation of revenue in the accounts of the
EDCTP-EEIG, the participating States and the EDCTP-EEIG will have to make the whole of the
financial documentation available to the Commission to enable it to carry out its financial audits,
indicating the timetable and consolidation of accounts for the EDCTP-EEIG.
The Commission will where necessary carry out such financial audits, in particular if it has
reasons to doubt the accuracy of the accounts in relation to the progress of the work described in
the activity reports.
The financial audits of the Community will be carried out either by its own employees or by
qualified accountants approved under the legislation governing the EDCTP-EEIG. The
Community will be free to choose the latter while however avoiding the risks of conflicts of
interests which could be pointed out by the participant who is the subject of the audit.
Moreover, in carrying out the research activities, the Commission will ensure that the financial
interests of the European Communities are protected by effective checks and, where
irregularities are detected, by proportionate and dissuasive measures and penalties.
To this end, rules concerning checks, measures and penalties, with references to Regulations
Nos 2988/95, 2185/96, 1073/1999 and 1074/1999, will be set out in the agreement signed
between the Commission and the EDCTP-EEIG.
In particular, the following points will have to be covered in the agreement:
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– inclusion of specific clauses to protect the financial interests of the European
Communities by carrying out checks and inspections of the funds granted;
– carrying out of administrative checks as part of anti-fraud measures, in accordance with
Regulations Nos 2185/96, 1073/1999 and 1074/1999;
– application of administrative penalties to all irregularities, whether deliberate or
negligent, in the implementation of the agreement, in accordance with general
Regulation No 2988/95;
– the fact that any recovery orders issued in the event of irregularities and fraud are
enforceable instruments under Article 256 of the EC Treaty.
